{"entity":{"id":"celcuity","kind":"company","name":"Celcuity","aka":[],"tldr":"Celcuity developed gedatolisib, approved in July 2026 for hormone-positive breast cancer.","summary":"Celcuity, based in Minneapolis and listed as CELC, developed gedatolisib, a pan-PI3K and mTOR inhibitor approved in July 2026 for hormone-receptor-positive breast cancer. Gedatolisib, sold as Revtorpyk, is given with palbociclib and fulvestrant, and the VIKTORIA-1 and VIKTORIA-2 trials are the evidence behind it. OnCo links it to HR-positive, HER2-negative breast cancer and to the gedatolisib drug record. Whether a pan-PI3K and mTOR inhibitor can be tolerated well enough in routine practice to displace mutation-selective PI3K drugs is the open question. Gedatolisib has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.celcuity.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["gedatolisib","serabelisib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06190899","nct05501886","nct06757634"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Minneapolis, MN","country":"US","companyType":"biotech","website":"https://www.celcuity.com","ticker":"CELC","investors":[],"funding":[]},"route":"/companies/celcuity/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/"},{"id":"serabelisib","kind":"drug","name":"Serabelisib","route":"/drugs/serabelisib/"}],"trial":[{"id":"nct06190899","kind":"trial","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06190899/"},{"id":"nct05501886","kind":"trial","name":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","route":"/trials/nct05501886/"},{"id":"nct06757634","kind":"trial","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","route":"/trials/nct06757634/"}],"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}]}}